Projects and strategic partnerships
Stablepharma has a strategic R&D and commercialisation partnership agreement in place with the European vaccine manufacturer BB-NCIPD Ltd (Bul Bio) with the aim to produce the world’s first ‘fridge free’ Td-StablevaX™ vaccine.
We have established partnerships with two leading UK Universities: University of Southampton to conduct our First in Human Clinical Trials for the Td vaccine; and the University of Strathclyde to progress our mRNA stabilisation project for Covid-19 vaccines.
Working with the UK’s The National Institute for Biological Standards and Control (NIBSC) to conduct animal trials we confirmed that the StablevaX™ tetanus vaccine to induce the same level of antibody response as the positive control vaccine.
Innovate UK is currently providing grant funding to Stablepharma to progress the R&D and product development work for the StablevaX™ Td vaccine.
Our white paper
StablevaX™ - a complementary technology for COVID-19 vaccines
In light of the ongoing Covid-19 pandemic, the challenge of equitable and efficient vaccine delivery has never appeared starker. Stablepharma believes that StablevaX™ could be a crucial complementary technology to currently available Covid-19 vaccines, especially those using mRNA-based approaches.
Our white paper
Illustrative Examples of Extraordinary stability of vaccines when dried in Trehalose
A world changing invention for the stabilisation of vaccines.
Receive our investor information pack
Please enter your details below to receive our investor information pack